Clinical Trials Browser

Phase 1/2 × Carcinoma, Ductal, Breast × Fulvestrant × Clear all

NCT02983071 2023-02-15

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms, Carcinoma, Ductal, Breast